SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(John Clara) srt2:(2005-2009)"

Sökning: WFRF:(John Clara) > (2005-2009)

  • Resultat 1-4 av 4
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Szatmari, Peter, et al. (författare)
  • Mapping autism risk loci using genetic linkage and chromosomal rearrangements.
  • 2007
  • Ingår i: Nature Genetics. - : Springer Science and Business Media LLC. - 1061-4036 .- 1546-1718. ; 39:3, s. 319-328
  • Tidskriftsartikel (refereegranskat)abstract
    • Autism spectrum disorders (ASDs) are common, heritable neurodevelopmental conditions. The genetic architecture of ASDs is complex, requiring large samples to overcome heterogeneity. Here we broaden coverage and sample size relative to other studies of ASDs by using Affymetrix 10K SNP arrays and 1,168 families with at least two affected individuals, performing the largest linkage scan to date while also analyzing copy number variation in these families. Linkage and copy number variation analyses implicate chromosome 11p12-p13 and neurexins, respectively, among other candidate loci. Neurexins team with previously implicated neuroligins for glutamatergic synaptogenesis, highlighting glutamate-related genes as promising candidates for contributing to ASDs.
  •  
2.
  • Leachman, Sancy A., et al. (författare)
  • Selection criteria for genetic assessment of patients with familial melanoma
  • 2009
  • Ingår i: Journal of American Academy of Dermatology. - : Elsevier BV. - 0190-9622. ; 61:4, s. 677-684
  • Forskningsöversikt (refereegranskat)abstract
    • Approximately 5% to 10% of melanoma may be hereditary in nature, and about 2% of melanoma can be specifically attributed to pathogenic germline mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A). To appropriately identify the small proportion of patients Who benefit most from referral to a genetics specialist for consideration of genetic testing for CDKN2A, We have reviewed available published studies of CDKN2A mutation analysis in cohorts with invasive, cutaneous melanoma and found variability in the rate of CDKN2A mutations based on geography, ethnicity, and the type of study and eligibility criteria used. Except in regions of high melanoma incidence, such as Australia, we found higher rates of CDKN2A positivity in individuals with 3 or more primary invasive melanomas and/or families with at least one invasive melanoma and two or more other diagnoses of invasive melanoma and/or pancreatic cancer among first- or second-degree relatives on the same side of the family. The Work summarized in this review should help identify individuals who are appropriate candidates for referral for genetic consultation and possible testing. (J Am Acad Dermatol 2009;61:677-84.)
  •  
3.
  • Anghel, Clara, et al. (författare)
  • Gas-tight oxides – Reality or just a Hope
  • 2006
  • Ingår i: Materials Science Forum. - 0255-5476 .- 1662-9752. ; 522-523, s. 93-101
  • Tidskriftsartikel (refereegranskat)abstract
    • A better understanding of the transport properties of gases in oxides is certainly very important in many applications. In the case of metals, a general protection measure against corrosion implies formation of a dense metal oxide scale. The scale should act as a barrier against gas transport and consequently it needs to be gas-tight. This is often assumed but rarely, if ever, confirmed. Hence there is a need for characterization of micro- and/or meso- pores formed especially during the early oxidation stage of metallic materials. This paper presents a novel and relatively straightforward method for characterization of gas release from an oxide previously equilibrated in a controlled atmosphere. The geometry of the sample is approximated to be a plate. The plate can be self-supporting or constitute a scale on a substrate. A mathematical model for calculation of diffusivity and gas content is given for this geometry. A desorption experiment, involving a mass spectrometer placed in ultra high vacuum, can be used to determine diffusivity and amount of gas released with aid of the mathematical model. The method is validated in measurements of diffusivity and solubility of He in quartz and applied in characterization of two Zr-oxides and one Fe oxide. From the outgassed amounts of water and nitrogen the H2O/N-2 molar ratio can be used to estimate an effective pore size in oxides.
  •  
4.
  • Tefferi, Ayalew, et al. (författare)
  • Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis : recommendations from an ad hoc international expert panel
  • 2007
  • Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 110:4, s. 1092-1097
  • Tidskriftsartikel (refereegranskat)abstract
    • The Janus kinase 2 mutation, JAK2V617F, is myeloid neoplasm-specific; its presence excludes secondary polycythemia, or thrombocytosis or bone marrow fibrosis from other causes. Furthermore, JAK2V617F or a JAK2 exon 12 mutation is present in virtually all patients with polycythemia vera (PV) whereas JAK2V617F also occurs in approximately half of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF). Therefore, JAK2 mutation screening holds the promise of a decisive diagnostic test in PV while being complementary to histology for the diagnosis of ET and PMF; the combination of molecular testing and histological review should also facilitate diagnosis of ET associated with borderline thrombocytosis. Accordingly, revision of the current World Health Organization (WHO) diagnostic criteria for PV, ET, and PMF is warranted; JAK2 mutation analysis should be listed as a major criterion for PV diagnosis and the platelet count threshold for ET diagnosis can be lowered from 600 to 450 x 109/L. The current document was prepared by an international expert panel of pathologists and clinical investigators in myeloproliferative disorders; it was subsequently presented to members of the Clinical Advisory Committee for the revision of the WHO Classification of Myeloid Neoplasms who endorsed the document and recommended its adoption by the WHO.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-4 av 4

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy